Courses

← vista completa

Published on May 1, 2006 | http://doi.org/10.5867/medwave.2006.04.3387

Cervical cancer: basic elements of carcinogenesis

Cáncer cervicouterino: elementos básicos de la carcinogénesis

Marco Puga A.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Marco Puga A.

Ginecólogo Oncólogo, Universidad de Chile, Santiago, Chile
Sociedad Chilena de Obstetricia y Ginecología

Figures

Article has no figures.

Forum

No messages

History

Citation Puga A. M. Cervical cancer: basic elements of carcinogenesis. Medwave 2006;6(04):e3387 doi: 10.5867/medwave.2006.04.3387

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/05/2006

Index

Metrics

Not available at the moment.

Notes

References

  1. Cervical Cancer Screening in Developing Countries. Report of a WHO Consultation. Geneva: World health Organization, 2002. | Link
  2. Parkin DM, Bray FI, Devesa SS. Cancer Burden in the year 2000. The Global Picture. Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66. | CrossRef | PubMed
  3. Ferlay J, Pisani P, Parkin DM. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press, 2001. | Link
  4. Ries LAG, Eisner M, Kosary C. SEER Cancer Statistics Review, 1975-2000. Bethesda MD, National Cancer Institute, 2003.
  5. Orientaciones para la Pesquisa y control del Cáncer Cervicouterino. Chile: Ministerio de Salud, 1998. | Link
  6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999 Sep;189(1):12-9. | CrossRef | PubMed
  7. Herrington CS. Do HPV-negative cervical carcinomas exist? -- Revisited. J Pathol. 1999 Sep;189(1):1-3. | CrossRef | PubMed
  8. Bekkers RL, Massuger LF, Bulten J, Melchers WJ. Epidemiological and clinical aspects of human papillomavirus detection in the prevention of cervical cancer. Rev Med Virol. Rev Med Virol. 2004 Mar-Apr;14(2):95-105. | CrossRef | PubMed
  9. Bohmer G, van den Brule AJ, BrummerO et al, No confirmed case of human papillomavirus DNA-negative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am J Obstet Gynecol. 2003 Jul;189(1):118-20. | CrossRef | PubMed
  10. Franceschi S. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer. Recent Results Cancer Res. 2005;166:277-97. | CrossRef | PubMed
  11. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV.. The causal relation between HPV and cervical cancer. J Clin Pathol. 2002 Apr;55(4):244-65. | CrossRef | PubMed
  12. Muñoz N. Human papillomavirus and cancer: The epidemiological evidence (Review). J Clin Virol. 2000 Oct;19(1-2):1-5. | CrossRef | PubMed
  13. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003 Feb 6;348(6):518-27. | CrossRef | PubMed
  14. Piver S. Oncología Ginecológica. 2ª edición. Madrid: Editorial Marban; cápitulo 6:85-110.
  15. Holowaty P, Miller AB, Rohan T, To T. Natural history of dysplasia of the uterine cervix. J Natl Cancer Inst. 1999 Feb 3;91(3):252-8. | CrossRef | PubMed
  16. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med. 1997 May 5;102(5A):3-8. | CrossRef | PubMed
  17. Clifford G, Smith J, Plummer M. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer. 2003 Jan 13;88(1):63-73. | CrossRef | PubMed
  18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002 May;2(5):342-50. | CrossRef | PubMed
  19. Choo K, Pan C, Han S. Integration of human papillomavirus type16 into cellular DNA of cervical carcinoma.: Prefential deletion of E2 gene and inavariable retention of E6 /E7 OFR. Virology. 1987 Nov;161(1):259-61. | CrossRef | PubMed
  20. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990 Dec 21;63(6):1129-36. | CrossRef | PubMed
  21. Klingelhutz A, Foster S, McDougall JK.Telomerase activationby the E6 geneproduct of human papillomavirus type 16. Nature. 1996 Mar 7;380(6569):79-82. | CrossRef | PubMed
  22. Lee DK, Kim BC, Kim IY, Cho EA, Satterwhite DJ, Kim SJ. The Human papillomavirus E7 oncoprotein inhibits TGB beta by blocking binding of the SMAD complex to its target sequence. J Biol Chem. 2002 Oct 11;277(41):38557-64. Epub 2002 Jul 26. | CrossRef | PubMed
  23. Duensing S, Munger K The Human Papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002 Dec 1;62(23):7075-82. | CrossRef | PubMed
  24. Wilson VG, West M, Woytek K, Rangasamy D. Papillomaviru E1 proteins: Form, function, and features. Virus Genes. 2002 Jun;24(3):275-90. | CrossRef | PubMed
  25. Tsai T, Chen SL. The biochemical and biological functions of human papillomavirus type 16 E5 oncoprotein. Arch Virol. 2003 Aug;148(8):1445-53. | CrossRef | PubMed
  26. Castellsagué X, Bosch FX, Muñoz N. Environmental co-factors in HPV carcinogenesis. Virus Res. 2002 Nov;89(2):191-9. | CrossRef | PubMed
  27. Matsumoto K, Yasugi T, Nakagawa S, Okubo M, Hirata R, Maeda H, et al. Human papillomavirus type 16 E6 variants and HLA class II alleles among Japanese women with cervical cancer. Int J Cancer. 2003 Oct 10;106(6):919-22. | CrossRef | PubMed
  28. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002 Feb;84(2):263-70. | CrossRef | PubMed
  29. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, et al. Smoking and cervical cancer: pooled analysis of the IARC multicentric case-control study. Cancer Causes Control. 2003 Nov;14(9):805-14. | CrossRef | PubMed
  30. Castellsagué X, Muñoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;(31):20-8. | PubMed
  31. Gershenson D. Gynecologic Cancer Controversies in Management. Elsivier Ltd, 2004.
  32. Prokopczyk B, Cox JE, Hoffmann D, Waggoner SE.identification of tobacco-specific carcinogens in the cervical mucus of smokers and no smokers. J Natl Cancer Inst. 1997 Jun 18;89(12):868-73. | CrossRef | PubMed
  33. Prokopczyk B, Trushin N, Leszczynska J, Waggoner SE, El-Bayoumy K. Human cervical tissue metabolizes the tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, via á- hydroxylation and carbonyl reduction pathways. Carcinogenesis. 2001 Jan;22(1):107-14. | CrossRef | PubMed
  34. Melikian AA, Wang X, Waggoner S, Hoffmann D, El-Bayoumy K. Comparative response of normal and of human papillomavirus 16 inmortalized human epithelial cervical cell to benzo(a)pirene. Oncol Rep. 1999 Nov-Dec;6(6):1371-6. | PubMed
  35. Smith JS, Green J, Berrington de Gonzalez A, Appleby P, Peto J, et al. Cervical cancer and use of hormonal contraceptives: A systematic Review. Lancet. 2003 Apr 5;361(9364):1159-67. | CrossRef | PubMed
  36. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, et al.Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC multicentric case-control study. Lancet. 2002 Mar 30;359(9312):1085-92. | CrossRef | PubMed
  37. Green J, Berrington de Gonzalez A, Smith JS, Franceschi S, Appleby P, Plummer M, et al. Human Papillomavirus infection and use of oral contraceptives. Br J Cancer. 2003 Jun 2;88(11):1713-20. | CrossRef | PubMed
  38. Gershenson D. Gynecologic Cancer Controversies in Management. Elsivier Ltd, 2004.
  39. Hildesheim A, Wnag S. Host and viral genetics and risk of cervical cancer: A review. Virus Res. 2002 Nov;89(2):229-40. | CrossRef | PubMed
  40. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998 May 21;393(6682):229-34. | CrossRef | PubMed
  41. Ojeda JM, Ampuero S, Rojas P, Prado R, Allende JE, Barton SA, et al. p53 codon 72 polymorphism and risk of cervical cancer. Biol Res. 2003;36(2):279-83. | CrossRef | PubMed
  42. Jee SH, Won SY, Yun JE, Lee JE, Park JS, et al. Polymorphism p53 codon-72 and invasive cervical cancer: a meta-analysis. Int J Gynaecol Obstet. 2004 Jun;85(3):301-8. | CrossRef | PubMed
  43. Contreras D, Cobos E, Lox C. Evaluation of the circulating fraction of the Her 2 /neu oncogene in patients with cervical cancer. Eur J Gynaecol Oncol. 2002;23(6):491-5. | PubMed
  44. Gaffney DK, Holden J, Davis M, Zempolich K, Murphy KJ, Dodson M. Elevated COX2 expression correlates with disminished survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2001 Apr 1;49(5):1213-7. | CrossRef | PubMed